News
-
-
PRESS RELEASE
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025
GENFIT presents promising new preclinical data on NTZ/G1090N for the treatment of ACLF at The Liver Meeting® 2025. G1090N optimizes dosing flexibility for varying patient conditions -
-
PRESS RELEASE
GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market
GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market. Decision reflects strategic intent for operational efficiency -
-
-
-
-
-
PRESS RELEASE
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
GENFIT discontinues VS-01 program in ACLF and shifts focus to UCD due to safety concerns. The company aims to accelerate other assets in ACLF, while exploring CCA data and reducing operating expenses